EPIDEMIOLOGICAL DYNAMIC MODELING OF HUMAN PAPILLOMAVIRUS-RELATED DISEASES TO ASSESS VACCINATION STRATEGIES IN ARGENTINA

被引:0
|
作者
Borracci, Raul A. [1 ]
Segal, Silvia, V [2 ]
Hendez, Jose H. [3 ]
机构
[1] Univ Austral, Fac Ciencias Biomed, Bioestadist, Buenos Aires, DF, Argentina
[2] Hosp Ninos Dr Ricardo Gutierrez, Buenos Aires, DF, Argentina
[3] Hosp Aleman, Dept Pediat, Buenos Aires, DF, Argentina
关键词
human papillomavirus; vaccines; cancer; epidemiology; mathematical model; SQUAMOUS-CELL CARCINOMAS; INVASIVE CERVICAL-CANCER; COST-EFFECTIVENESS; MATHEMATICAL-MODELS; HPV VACCINATION; INTRAEPITHELIAL NEOPLASIA; PROGNOSTIC VALUE; NATURAL-HISTORY; UNITED-STATES; IMPACT;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Our objective was to develop and test a dynamic simulation model of human papillomavirus (HPV) related diseases to assess rational vaccination strategies in Argentina. A dynamic stochastic transmission model for hetero- and homosexual transmission of HPV oncogenic and low-risk oncogenic types among females and males was developed. The model included HPV transmission and vaccination, the natural history of HPV-related diseases, disease outcomes, and cervical cancer screening. Considering all cervical cancers, covered or not by the current quadrivalent vaccine, the existing coverage rate would lead to 60% reduction in the global incidence of cervical cancer at 25 years, and to 79% at 50 years. Isolated current female vaccination without a screening program would need around 100 years to eliminate cervical cancer from the local population. Current coverage rate would lead to 59% reduction of vulvar cancer, 76% of vaginal cancer, 85% of anal cancer, and 87% of oropharyngeal cancer, estimated over a 25-year time prospect. Female HPV vaccination within the context of current cervical cancer screening should reach a minimum long-term mean coverage of 60% of girls, receiving at least a two-dose vaccine schedule, to significantly reduce or virtually eliminate cervical cancer at 50 years. Including vaccination to boys to improve herd immunity did not influence the incidence of cervical cancer over time, as long as female coverage did not fall below 50%. Regarding vulvar, vaginal, anal, penile, and some oropharyngeal cancers, current girls-only based vaccination could virtually eliminate these cancer types after 35-40 years, both in women and men.
引用
收藏
页码:315 / 328
页数:14
相关论文
共 50 条
  • [21] Therapy of Human Papillomavirus-Related Disease
    Stern, Peter L.
    van der Burg, Sjoerd H.
    Hampson, Ian N.
    Broker, Thomas R.
    Fiander, Alison
    Lacey, Charles J.
    Kitchener, Henry C.
    Einstein, Mark H.
    VACCINE, 2012, 30 : F71 - F82
  • [22] Human papillomavirus-related oropharyngeal carcinoma
    Saito, Yuki
    Homma, Akihiro
    Kiyota, Naomi
    Tahara, Makoto
    Hanai, Nobuhiro
    Asakage, Takahiro
    Matsuura, Kazuto
    Ota, Ichiro
    Yokota, Tomoya
    Sano, Daisuke
    Kodaira, Takeshi
    Motegi, Atsushi
    Yasuda, Koichi
    Takahashi, Shunji
    Tanaka, Kaoru
    Onoe, Takuma
    Okano, Susumu
    Imamura, Yoshinori
    Ariizumi, Yosuke
    Hayashi, Ryuichi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 52 (07) : 692 - 698
  • [23] Human papillomavirus-related oropharyngeal cancer
    Taberna, M.
    Mena, M.
    Pavon, M. A.
    Alemany, L.
    Gillison, M. L.
    Mesia, R.
    ANNALS OF ONCOLOGY, 2017, 28 (10) : 2386 - 2398
  • [24] Human papillomavirus-related tumors in HIV
    Palefsky, Joel
    CURRENT OPINION IN ONCOLOGY, 2006, 18 (05) : 463 - 468
  • [25] Preventing cervical cancer and other human papillomavirus-related diseases: Recent advances in prophylactic vaccination - Introduction to vaccine supplement
    Villa, LL
    VACCINE, 2006, 24 : 1 - 1
  • [26] Awareness and knowledge of human papillomavirus-related diseases are still dramatically insufficient in the era of high-coverage vaccination programs
    Capogrosso, Paolo
    Ventimiglia, Eugenio
    Matloob, Rayan
    Colicchia, Michele
    Serino, Alessandro
    Castagna, Giulia
    Clementi, Maria Chiara
    La Croce, Giovanni
    Capitanio, Umberto
    Gandaglia, Giorgio
    Damiano, Rocco
    Mirone, Vincenzo
    Montorsi, Francesco
    Salonia, Andrea
    WORLD JOURNAL OF UROLOGY, 2015, 33 (06) : 873 - 880
  • [27] Awareness and knowledge of human papillomavirus-related diseases are still dramatically insufficient in the era of high-coverage vaccination programs
    Paolo Capogrosso
    Eugenio Ventimiglia
    Rayan Matloob
    Michele Colicchia
    Alessandro Serino
    Giulia Castagna
    Maria Chiara Clementi
    Giovanni La Croce
    Umberto Capitanio
    Giorgio Gandaglia
    Rocco Damiano
    Vincenzo Mirone
    Francesco Montorsi
    Andrea Salonia
    World Journal of Urology, 2015, 33 : 873 - 880
  • [28] Cost analysis of Human Papillomavirus-related cervical diseases and genital warts in Swaziland
    Ginindza, Themba G.
    Sartorius, Benn
    Dlamini, Xolisile
    Ostensson, Ellinor
    PLOS ONE, 2017, 12 (05):
  • [29] MANAGEMENT OF EXCEPTIONAL PAPILLOMAVIRUS-RELATED DISEASES BY BCG IMMUNOSTIMULATION
    BIR, M
    ROUILLEAULT, P
    SEMAINE DES HOPITAUX, 1988, 64 (22): : 1525 - 1528
  • [30] Can Male Vaccination Reduce the Burden of Human Papillomavirus-Related Disease in the United States?
    Low, Garren M. I.
    Attiga, Yasser S.
    Garg, Gaurav
    Schlegal, Richard
    Gallicano, G. Ian
    VIRAL IMMUNOLOGY, 2012, 25 (03) : 174 - 186